Solithromycin

Drug Profile

Solithromycin

Alternative Names: CEM-101; OP-1068; T-4288

Latest Information Update: 23 May 2017

Price : $50

At a glance

  • Originator Optimer Pharmaceuticals
  • Developer Cempra Pharmaceuticals; Toyama Chemical
  • Class Anti-infectives; Antibacterials; Antimalarials; Heterocyclic bicyclo compounds; Ketolides; Macrolides; Oxazoles; Pyrans; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Community-acquired pneumonia
  • Phase III Bronchitis; Chlamydial infections; Gonorrhoea; Otorhinolaryngological infections; Respiratory tract infections; Urethritis
  • Phase II Chronic obstructive pulmonary disease; Non-alcoholic steatohepatitis
  • Phase I Anthrax; Bacterial infections; Tularaemia
  • Preclinical Cystic fibrosis; Eye disorders; Obstetric and gynaecological infections; Otitis media
  • Research Enterococcal infections; Legionella infections; Mycoplasma infections
  • No development reported Malaria; Mycobacterium avium complex infections

Most Recent Events

  • 10 May 2017 Preclinical trials in Eye disorders in USA (Ophthalmic)
  • 28 Mar 2017 Regulatory submission withdrawn for Community-acquired pneumonia in European Union (IV)
  • 28 Mar 2017 Regulatory submission withdrawn for Community-acquired pneumonia in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top